DK3130592T3 - ANALOGER AF 4H-PYRAZOLO[1,5-á]BENZIMIDAZOL-FORBINDELSER SOM PARPINHIBITORER - Google Patents

ANALOGER AF 4H-PYRAZOLO[1,5-á]BENZIMIDAZOL-FORBINDELSER SOM PARPINHIBITORER Download PDF

Info

Publication number
DK3130592T3
DK3130592T3 DK15777444T DK15777444T DK3130592T3 DK 3130592 T3 DK3130592 T3 DK 3130592T3 DK 15777444 T DK15777444 T DK 15777444T DK 15777444 T DK15777444 T DK 15777444T DK 3130592 T3 DK3130592 T3 DK 3130592T3
Authority
DK
Denmark
Prior art keywords
parpin
hibitors
pyrazolo
analogs
benzimidazole compounds
Prior art date
Application number
DK15777444T
Other languages
English (en)
Inventor
Zhaozhong Ding
Shuhui Chen
Gang Li
Cailin Wang
Zhibo Zhang
Ronghua Tu
Yang Yue
Hailiang Chen
Wenjie Sun
Lu Huang
Original Assignee
Hubei Bio Pharmaceutical Industrial Tech Institute Inc
Humanwell Healthcare Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201410144173.0A external-priority patent/CN104974161B/zh
Application filed by Hubei Bio Pharmaceutical Industrial Tech Institute Inc, Humanwell Healthcare Group Co Ltd filed Critical Hubei Bio Pharmaceutical Industrial Tech Institute Inc
Application granted granted Critical
Publication of DK3130592T3 publication Critical patent/DK3130592T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/424Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK15777444T 2014-04-10 2015-03-30 ANALOGER AF 4H-PYRAZOLO[1,5-á]BENZIMIDAZOL-FORBINDELSER SOM PARPINHIBITORER DK3130592T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410144173.0A CN104974161B (zh) 2014-04-10 2014-04-10 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物
CN201510113090 2015-03-13
PCT/CN2015/075363 WO2015154630A1 (zh) 2014-04-10 2015-03-30 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物

Publications (1)

Publication Number Publication Date
DK3130592T3 true DK3130592T3 (da) 2019-11-04

Family

ID=54287319

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15777444T DK3130592T3 (da) 2014-04-10 2015-03-30 ANALOGER AF 4H-PYRAZOLO[1,5-á]BENZIMIDAZOL-FORBINDELSER SOM PARPINHIBITORER

Country Status (22)

Country Link
US (1) US9856262B2 (da)
EP (1) EP3130592B1 (da)
JP (1) JP6359175B2 (da)
KR (1) KR101921486B1 (da)
CN (1) CN106459057B (da)
AU (1) AU2015245786B2 (da)
BR (1) BR112016023397B1 (da)
CA (1) CA2944801C (da)
DK (1) DK3130592T3 (da)
ES (1) ES2754590T3 (da)
HU (1) HUE047410T2 (da)
IL (1) IL248258B (da)
MX (1) MX368496B (da)
NZ (1) NZ725165A (da)
PL (1) PL3130592T3 (da)
PT (1) PT3130592T (da)
RU (1) RU2672722C2 (da)
SA (1) SA516380051B1 (da)
SG (1) SG11201608438YA (da)
TW (1) TWI671301B (da)
WO (1) WO2015154630A1 (da)
ZA (1) ZA201607736B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104974161B (zh) * 2014-04-10 2019-11-01 湖北生物医药产业技术研究院有限公司 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物
CA3003122C (en) 2015-09-30 2023-10-03 Medshine Discovery Inc. Salt type and crystal type of 4h-pyrazolo[1, 5-alpha]benzimidazole compound and preparation method and intermediate thereof
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
KR102596307B1 (ko) 2017-04-27 2023-10-30 바이엘 애니멀 헬스 게엠베하 새로운 비시클릭 피라졸 유도체
CN115028641B (zh) * 2022-07-19 2024-05-28 湖南大学 一种钴催化合成5,8-双官能团取代咪唑并[1,2-a]吡嗪类化合物的方法
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025056690A1 (en) 2023-09-12 2025-03-20 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Parp1- and immune-checkpoint inhibitors for the treatment of cancer patients overexpressing ubqln1 and/or ubqln4
CN116969954B (zh) * 2023-09-21 2023-11-28 广东省农业科学院农业质量标准与监测技术研究所 一类含内酰胺的三环稠合杂环化合物及其应用
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CN117534677B (zh) * 2024-01-09 2024-03-12 广东省农业科学院农业质量标准与监测技术研究所 一类含亚胺的三环稠合杂环化合物及其应用
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ras抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916051A (en) * 1987-04-07 1990-04-10 Konica Corporation Silver halide color photographic light-sensitive material
MY143499A (en) * 2003-12-22 2011-05-31 Sb Pharmco Inc Crf receptor antagonist and methods relating thereto
WO2007076127A2 (en) 2005-12-22 2007-07-05 Biogen Idec Ma Inc Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators
WO2007144669A1 (en) 2006-06-15 2007-12-21 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyrazolo[1,5-a]quinazolin-5(4h)-ones as inhibitors of poly(adp-ribose)polymerase (parp)
EP2069351B1 (en) * 2006-06-20 2015-10-28 AbbVie Inc. Pyrazoloquinazolinones as parp inhibitors
GB0701273D0 (en) * 2007-01-24 2007-02-28 Angeletti P Ist Richerche Bio New compounds
DK2656843T3 (da) 2012-04-26 2015-04-20 Helmut Schickaneder Estere af bendamustin og relaterede forbindelser, og medicinsk anvendelse deraf
AU2013257018B2 (en) * 2012-05-04 2017-02-16 Merck Patent Gmbh Pyrrolotriazinone derivatives
EP2666775A1 (en) * 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
CN104350056A (zh) 2012-06-07 2015-02-11 霍夫曼-拉罗奇有限公司 端锚聚合酶的吡咯并嘧啶酮和吡咯并吡啶酮抑制剂
ES2595240T3 (es) * 2012-07-09 2016-12-28 Lupin Limited Derivados de tetrahidroquinazolinona como inhibidores de PARP
CN103570725B (zh) 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
KR102083154B1 (ko) * 2012-08-08 2020-03-02 메르크 파텐트 게엠베하 (아자―)이소퀴놀리논 유도체
CN104974161B (zh) 2014-04-10 2019-11-01 湖北生物医药产业技术研究院有限公司 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物

Also Published As

Publication number Publication date
EP3130592B1 (en) 2019-08-14
HUE047410T2 (hu) 2020-04-28
CN106459057A (zh) 2017-02-22
CA2944801A1 (en) 2015-10-15
MX368496B (es) 2019-10-04
SA516380051B1 (ar) 2020-05-17
BR112016023397A2 (da) 2017-08-15
AU2015245786B2 (en) 2018-03-15
RU2672722C2 (ru) 2018-11-19
PL3130592T3 (pl) 2020-05-18
IL248258B (en) 2018-11-29
RU2016144202A (ru) 2018-05-15
SG11201608438YA (en) 2016-11-29
ES2754590T3 (es) 2020-04-20
TW201620913A (zh) 2016-06-16
TWI671301B (zh) 2019-09-11
KR101921486B1 (ko) 2018-11-26
CN106459057B (zh) 2019-06-07
US9856262B2 (en) 2018-01-02
EP3130592A4 (en) 2017-09-06
AU2015245786A1 (en) 2016-11-03
RU2016144202A3 (da) 2018-05-15
NZ725165A (en) 2018-04-27
EP3130592A1 (en) 2017-02-15
MX2016013265A (es) 2017-05-03
KR20170005807A (ko) 2017-01-16
JP6359175B2 (ja) 2018-07-18
CA2944801C (en) 2019-02-12
ZA201607736B (en) 2017-09-27
BR112016023397B1 (pt) 2022-08-16
WO2015154630A1 (zh) 2015-10-15
JP2017510653A (ja) 2017-04-13
US20170029430A1 (en) 2017-02-02
PT3130592T (pt) 2019-11-21

Similar Documents

Publication Publication Date Title
DK3130592T3 (da) ANALOGER AF 4H-PYRAZOLO[1,5-á]BENZIMIDAZOL-FORBINDELSER SOM PARPINHIBITORER
EP3558322A4 (en) ANTIVIRAL BENZYL AMINE PHOSPHODIAMIDE COMPOUNDS
DK3377488T3 (da) Heterocykliske forbindelser som immunomodulatorer
EP3532069A4 (en) ANTIVIRAL ARYL AMID PHOSPHODIAMID COMPOUNDS
HUE053819T2 (hu) Ciklikus dinukleotid-vegyületek
DK3472167T3 (da) Heterocykliske forbindelser som immunomodulatorer
DK3303348T3 (da) Naphthyridinforbindelser som JAK-kinaseinhibitorer
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
DK3461821T3 (da) Indolcarboxamidforbindelser, der er brugbar som kinasehæmmere
ME03419B (me) Supstituirani spojevi dihidroizokinolinona
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3357919T3 (da) Aromatiske heterocykliske forbindelser som antiinflammatoriske forbindelser
DK3277677T3 (da) 1-cyano-pyrrolidinforbindelser som usp30-hæmmere
LT3197883T (lt) Nauji junginiai
LT3157916T (lt) Heteroarilo junginiai, skirti kinazės inhibavimui
DK3298027T3 (da) Anthelmintiske depsipeptidforbindelser
DK3294713T3 (da) Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer
DK3194411T3 (da) Nukleotidanaloger
DK3204378T6 (da) N-pyridinylacetamidderivater som hæmmere af wnt-signaleringsbanen
DK3233813T3 (da) Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
DK3544981T3 (da) Benzodiazoliumforbindelser som enac-inhibitorer
EP3464336A4 (en) LINKS
DK3390407T3 (da) Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser
EP3310352A4 (en) CRYSTALLINE COMPOUNDS
DK3552017T3 (da) Forbindelser, der er anvendelige som ripk1-inhibitorer